Lastly, the lower percentage of HER2 positivity rate in our study may be due to a higher proportion of triple-negative breast cancer specimens sent to the testing laboratory (35.8 % (Caris, data on file) as compared to 15–20 % of the general breast cancer population [19, 41]). This evidence concerns the gene ERBB2 and breast cancer.